EUVIMEDEUVIMED entdecken
Crossref

Therapeutic peptides in inflammatory bowel disease: From mechanistic rationale to clinical translation

Hirannya Karunadasa, Abhinav Vasudevan

World Journal of Translational Medicine · 28.11.2026 · 12 (4)

DOI: 10.5528/wjtm.124866 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Translational Medicine, online erschienen am 28.11.2026. Verfasst von Hirannya Karunadasa und 1 weiteren Autor:innen. Die Arbeit nennt 124 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although therapeutic advancements have transformed treatment of inflammatory bowel disease (IBD), many patients fail to achieve a durable corticosteroid-free remission, highlighting an apparent therapeutic ceiling. This has prompted interest in novel treatment strategies that target pathways not yet fully addressed by existing therapies. Therapeutic peptides represent an emerging and mechanistically diverse class of agents with potential applications in IBD. Occupying an intermediate space between small molecules and biologics, peptides offer theoretical advantages including high target specificity, structural adaptability, capacity to modulate protein-protein interactions and relatively predictable metabolism. This narrative review summarises the rationale for the development of therapeutic peptides in IBD and evaluates key candidates across major mechanistic classes including anti-inflammatory, antimicrobial and barrier supportive peptides. Although preclinical findings and early clinical data are encouraging, substantial barriers to translation remain, including limited stability and bioavailability, delivery challenges, manufacturing complexity, incomplete long-term safety and efficacy data and regulatory considerations. Well-designed clinical trials are therefore required to establish efficacy, safety and optimal positioning of peptide-based therapies within existing treatment paradigms. Therapeutic peptides are unlikely to replace established therapies in the near term but may ultimately complement current IBD management by targeting additional disease pathways and expanding the therapeutic armamentarium.

Zitieren

APA

Karunadasa, H., & Vasudevan, A. (2026). Therapeutic peptides in inflammatory bowel disease: From mechanistic rationale to clinical translation. World Journal of Translational Medicine, 12(4). https://doi.org/10.5528/wjtm.124866

Vancouver

Karunadasa H, Vasudevan A. Therapeutic peptides in inflammatory bowel disease: From mechanistic rationale to clinical translation. World Journal of Translational Medicine. 2026;12(4). doi:10.5528/wjtm.124866

BibTeX
@article{Karunadasa2026,
  author = {Karunadasa, Hirannya and Vasudevan, Abhinav},
  title = {Therapeutic peptides in inflammatory bowel disease: From mechanistic rationale to clinical translation},
  journal = {World Journal of Translational Medicine},
  year = {2026},
  volume = {12},
  number = {4},
  doi = {10.5528/wjtm.124866}
}
Kostenlos starten →